No Data
No Data
TransCode Therapeutics Announces First Patient Dosed In Third Cohort With Lead Candidate In Phase 1 Clinical Trial; No Significant Safety Or Dose Limiting Toxicities Reported In Cohorts 1 And 2; PK Data From Cohorts 1 And 2 Consistent With Preclinical...
Express News | Transcode Therapeutics Announces First Patient Dosed in Third Cohort With Lead Candidate in Phase 1 Clinical Trial
TransCode Therapeutics Regains Nasdaq Listing Compliance; Stock Up
Express News | TransCode Therapeutics Regains Nasdaq Compliance For Minimum Bid Price, Shareholders' Equity, And Shareholder Approval Rule
H.C. Wainwright Maintains Transcode Therapeutics(RNAZ.US) With Buy Rating, Cuts Target Price to $20
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), TransCode Therapeutics (RNAZ)